Rasagiline Mylan Европейски съюз - норвежки - EMA (European Medicines Agency)

rasagiline mylan

mylan pharmaceuticals limited - rasagilintartrat - parkinsonsykdom - anti-parkinson medisiner - rasagilin mylan er indisert for behandling av idiopatisk parkinsons sykdom (pd) som monoterapi (uten levodopa) eller som tilleggsbehandling (med levodopa) hos pasienter med endt dosefluktuasjoner.

Rasagiline ratiopharm Европейски съюз - норвежки - EMA (European Medicines Agency)

rasagiline ratiopharm

teva b.v. - rasagilin - parkinsonsykdom - anti-parkinson medisiner - rasagiline ratiopharm er indisert for behandling av idiopatisk parkinsons sykdom (pd) som monoterapi (uten levodopa) eller supplement terapi (med levodopa) hos pasienter med slutten av dose svingninger.

Carbidopa/Levodopa Orion 25 mg / 100 mg Норвегия - норвежки - Statens legemiddelverk

carbidopa/levodopa orion 25 mg / 100 mg

orion corporation - karbidopamonohydrat / levodopa - tablett - 25 mg / 100 mg

Carbidopa/Levodopa Orion 12.5 mg / 50 mg Норвегия - норвежки - Statens legemiddelverk

carbidopa/levodopa orion 12.5 mg / 50 mg

orion corporation - karbidopamonohydrat / levodopa - tablett - 12.5 mg / 50 mg

Metoclopramide Accord 10 mg Норвегия - норвежки - Statens legemiddelverk

metoclopramide accord 10 mg

accord healthcare b.v. - metoklopramidhydrokloridmonohydrat - tablett - 10 mg

Dinetrel 100 mg Норвегия - норвежки - Statens legemiddelverk

dinetrel 100 mg

morningside healthcare (malta) limited - amantadinhydroklorid - kapsel, hard - 100 mg

Celsunax Европейски съюз - норвежки - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne pasienter, for å kunne skille mellom sannsynlig demens med lewy legemer fra alzheimers sykdom.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Carbidopa/Levodopa Fair-Med 12.5 mg / 50 mg Норвегия - норвежки - Statens legemiddelverk

carbidopa/levodopa fair-med 12.5 mg / 50 mg

fair-med healthcare gmbh - karbidopamonohydrat / levodopa - tablett - 12.5 mg / 50 mg

Carbidopa/Levodopa Fair-Med 25 mg / 100 mg Норвегия - норвежки - Statens legemiddelverk

carbidopa/levodopa fair-med 25 mg / 100 mg

fair-med healthcare gmbh - karbidopamonohydrat / levodopa - tablett - 25 mg / 100 mg

Sinemet 12,5/50 12.5 mg / 50 mg Норвегия - норвежки - Statens legemiddelverk

sinemet 12,5/50 12.5 mg / 50 mg

n.v. organon - kloosterstraat - karbidopa / levodopa - tablett - 12.5 mg / 50 mg